Arbutus Biopharma Corp 2025年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fromtoCommission File Number:001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) 98-0597776(I.R.S. EmployerIdentification No.) 701 Veterans Circle,Warminster,PA18974 (Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company☐☐☒☒☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May12, 2025, the registrant had191,527,129common shares, without par value, outstanding. Condensed Consolidated Statements of Operations and Comprehensive Loss(Unaudited) Condensed Consolidated Statements of Stockholders’ Equity(Unaudited) Condensed Consolidated Statements of Stockholders’ Equity(Unaudited)(In thousands of U.S. Dollars, except share amounts) Condensed Consolidated Statements of Cash Flows(Unaudited) ARBUTUS BIOPHARMA CORPORATION Notes to Condensed Consolidated Financial Statements (Tabular amounts in thousands of U.S. Dollars, except share and per share amounts) 1.Nature of business and future operations Description of the Business Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company focused on infectiousdisease.The Company is currently developing imdusiran(AB-729),its proprietary,GalNAc-conjugated,subcutaneously-deliveredribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B The Company continues to protect and defend its intellectual property, which is the subject of its ongoing lawsuits against ModernaTherapeutics, Inc. (Moderna) and against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of the Company’spatented lipid nanoparticle (LNP) delivery technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines.With respect to the Moderna lawsuit in the United States, a trial date has been set for September 29, 2025. With respect to thePfizer/BioNTech lawsuit, the claim construction hearing occurred in December 2024. The court is expected to provide its ruling on thePfizer/BioNTech lawsuit claim construction and issue a further scheduling order, including the date for trial, in 2025. On March 3, 2025, the Liquidity At March31, 2025, the Company had an aggregate of $112.7million in cash, cash equivalents and investments in marketable securities. TheCompany hadnooutstanding debt as of March31, 2025. The Company believes it has sufficient cash resources to fund its operations for at 2.Significant accounting policies Basis of presentation and principles of consolidation These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally acceptedaccounting principles for interim financial statements and accordingly, do not include all disclosures required for annual financialstatements. These statements should be read in conjunction with the Company’s audited consolidated financial statements and notes theretofor the year ended December31, 2024 included in the Company’s Annual Report on Form 10-K for the year ended December31, 2024.These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and itsonewholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary tofair